All lobbying filings

LUNDBECK LLC

Lobbying for LUNDBECK LLC

Filing 2nd Quarter - Report

2nd Quarter (Apr 1 - June 30) 2025 · District of Columbia · House · Senate · $170,000.00 expenses · posted Jul 18, 2025

Official filing document

Bills named in this filing 4

HR 946
ORPHAN Cures Act
HR 1492
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic can…
S 832
EPIC Act of 2025
HR 1
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.

Lobbying activity 4

Health Issues

Issues pertaining to Pharmacy Benefit Managers Step therapy reform -the Safe Step Act Neuroscience Drug Program - FY 2026 AgFDA Approps BRAIN Initiative - FY 2026 Labor-HHS Appropriations Migraine care - FY 2026 MilCon Approps

Medicare/Medicaid

Issues pertaining to the 340B Drug Discount Program Issues pertaining to the implementation of the Inflation Reduction Act of 2022 Issues pertaining to Pharmacy Benefit Managers Issues pertaining to CMS Coverage of APS in LTC Issues pertaining to Medicares Six Protected Classes policy Medicare Part D Smoothing Benefit - FY 2026 Labor-HHS Appropriations Orphan drug exclusion in the Inflation Reduction Act - H.R. 946 - The ORPHAN Cures Act Small molecule discrepancy in the Inflation Reduction Act - H.R. 1492 & S. 832 - The EPIC Act Issues pertaining to the Most Favored Nation drug price setting policy - H.R. 1 - One Big Beautiful Bill Act

Taxation/Internal Revenue Code

R&D Tax Credit

Trade (domestic/foreign)

Tariffs on pharmaceutical products

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.